"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
The manufacturer of darunavir/cobicistat (Prezcobix) has issued a Dear Doctor letter warning about use of the drug during pregnancy due to significantly reduced plasma levels of the drug during the second and third trimesters.
A drug combination aimed at preventing transmission of HIV from a pregnant woman to her fetus likely does not increase the risk for preterm birth and early infant death, according to a re-analysis of two studies.
This recently updated fact sheet from the U.S. Centers for Disease Control and Prevention provides a quick rundown of the latest HIV infection numbers and prevention challenges impacting new moms and moms-to-be.
Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.
The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants.
The British HIV Association has taken the unusual step of issuing a statement to publicly challenge a recent paper from the British Medical Journal.
"We were, frankly, shocked and appalled to see a CDC guidance rife with outdated and misleading information that implied otherwise," JD Davids states. "Today, CDC has not only corrected these errors but also released an updated analysis that shows re...
The CDC is now "in line with current science and supports a patient-centered approach," said Shannon Weber, M.S.W., which can mean "accessible safer-conception options for thousands of Americans living and loving with HIV."
Some heterosexual men living with HIV assume they have to forego fatherhood and mixed-status relationships. Providers can help dispel these misconceptions by having conversations about reproductive health with their patients.